Al18F-NOTA-LM3 PET/CT in Patients With TIO
ConditionTumor-Induced Osteomalacia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorPeking Union Medical College Hospital
About this trial
This is a pilot study to assess the value of whole-body Al18F-NOTA-LM3 PET/CT in patients with tumor-induced osteomalacia.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged 18 to 80 years.
Suspected or confirmed TIO patients.
Disqualifiers
Combined with other types of tumors.
Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR<30ml/min).
Pregnant or breast-feeding women.
Inability to perform PET/CT scans.
Trial design
Design model
Single group
Treatments tested in this trial
Diagnostic Test: Al18F-NOTA-LM3
DrugAl18F-NOTA-LM3 will be injected into the patients. Patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
Diagnostic Test: 68Ga-DOTATATE
Drug68Ga-DOTATATE will be injected into the patients. Patients will undergo a whole-body PET/CT scan 40-60 minutes after injection.
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: Al18F-NOTA-LM3 and 68Ga-DOTATATE PET/CT scanExperimental treatment 2 interventions
Trial outcomes
Primary outcomes
1
Diagnostic value
Sensitivity and specificity of Al18F-NOTA-LM3 PET/CT for TIO in comparison with 68Ga-DOTATATE PET/CT
Time frame
From study completion to 6 months after completion.Secondary outcomes
1
standardized uptake value (SUV) of tumor
Compare the SUVmax of tumor derived from Al18F-NOTA-LM3 and 68Ga-DOTATATE PET/CT.
Time frame
From study completion to 6 months after completion.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov